269 related articles for article (PubMed ID: 25294913)
21. A phase II study of REOLYSIN
Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J
Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863
[TBL] [Abstract][Full Text] [Related]
22. CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway.
Park EH; Park EH; Cho IR; Srisuttee R; Min HJ; Oh MJ; Jeong YJ; Jhun BH; Johnston RN; Lee S; Koh SS; Chung YH
Cancer Gene Ther; 2010 May; 17(5):307-14. PubMed ID: 20075984
[TBL] [Abstract][Full Text] [Related]
23. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Gollamudi R; Ghalib MH; Desai KK; Chaudhary I; Wong B; Einstein M; Coffey M; Gill GM; Mettinger K; Mariadason JM; Mani S; Goel S
Invest New Drugs; 2010 Oct; 28(5):641-9. PubMed ID: 19572105
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
25. Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.
Kawagishi T; Kanai Y; Nouda R; Fukui I; Nurdin JA; Matsuura Y; Kobayashi T
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907973
[TBL] [Abstract][Full Text] [Related]
26. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Jaime-Ramirez AC; Yu JG; Caserta E; Yoo JY; Zhang J; Lee TJ; Hofmeister C; Lee JH; Kumar B; Pan Q; Kumar P; Baiocchi R; Teknos T; Pichiorri F; Kaur B; Old M
Mol Ther Oncolytics; 2017 Jun; 5():87-96. PubMed ID: 28812060
[TBL] [Abstract][Full Text] [Related]
27. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
28. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Cohn DE; Sill MW; Walker JL; O'Malley D; Nagel CI; Rutledge TL; Bradley W; Richardson DL; Moxley KM; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):477-483. PubMed ID: 28756871
[TBL] [Abstract][Full Text] [Related]
32. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C; Spicer J; Protheroe A; Roulstone V; Twigger K; White CM; Vile R; Melcher A; Coffey MC; Mettinger KL; Nuovo G; Cohn DE; Phelps M; Harrington KJ; Pandha HS
Clin Cancer Res; 2010 Nov; 16(22):5564-72. PubMed ID: 20926400
[TBL] [Abstract][Full Text] [Related]
33. Reovirus modulates autophagy during oncolysis of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Autophagy; 2013 Mar; 9(3):413-4. PubMed ID: 23322106
[TBL] [Abstract][Full Text] [Related]
34. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C; Kuruvilla S; Keith BD; Torri V; Blais N; Hao D; Korpanty GJ; Goss G; Melosky BL; Mates M; Leighl N; Ayoub JP; Sederias J; Feilotter H; Seymour L; Laurie SA
Lung Cancer; 2018 Jun; 120():142-148. PubMed ID: 29748010
[TBL] [Abstract][Full Text] [Related]
35. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
36. Advances in viral oncolytics for treatment of multiple myeloma - a focused review.
Sarwar A; Hashim L; Faisal MS; Haider MZ; Ahmed Z; Ahmed TF; Shahzad M; Ansar I; Ali S; Aslam MM; Anwer F
Expert Rev Hematol; 2021 Dec; 14(12):1071-1083. PubMed ID: 34428997
[TBL] [Abstract][Full Text] [Related]
37. Infection and killing of multiple myeloma by adenoviruses.
Senac JS; Doronin K; Russell SJ; Jelinek DF; Greipp PR; Barry MA
Hum Gene Ther; 2010 Feb; 21(2):179-90. PubMed ID: 19788385
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
[TBL] [Abstract][Full Text] [Related]
39. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic virotherapy for multiple myeloma.
Stief AE; McCart JA
Expert Opin Biol Ther; 2008 Apr; 8(4):463-73. PubMed ID: 18352850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
